Research focus/cooperations
Research focus: Translational prostate cancer research
| since 2018 | Deep learning for prostate cancer MRI diagnosis (Dr. Gabrani, IBM Zürich Research Laboratory, PD Dr. Patak, Klinik Hirslanden Zürich) |
| since 2016 | Co-Coordinator, Phase IIIb randomized trial comparing irradiation plus long-term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCG (Pegasus), EORTC protocol 1414 ROG-GUCG |
| since 2014 | MRI-characteristics of locally advanced Prostate Cancer (Prof. Hadaschik, PD Dr. Wetter, Universität Essen) |
| since 2013 | Co-PI, Perioperative anti-PD-L1 antibody durvalumab (MEDI4736) in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer, SAKK 06/17 |
| since 2011 | Movember Global Action Plan 6 (GAP6) Oligometastatic Prostate cancer, Steering committee member (Movember foundation, Australia, USA) |
| since 2007 | Identification of genomic determinants of tumor and metastasis heterogeneity of high risk prostate cancer and development of a lethal prostate cancer panel. (Prof. Rubin, PD Dr. Kruithof de Julio, Bern) |
| since 2007 | Tissue Metabolomic profiles and their alterations in surgically treated high risk prostate cancer. Institute of Pathology, Helmholtz Zentrum München, German Research Center for Environmental Health (Prof. A. Walch) |
| since 2007 | Serum Metabolomic profiles and their alterations in prostate cancer, University Institute for Clinical Chemistry, University of Bern (Profs. M. Fiedler, C. Largadier) |
| since 2007 | EORTC (European Organisation for Research and Treatment of Cancer) |
| since 2007 | Coordinator of the interdisciplinary translational research platform SPECTApros (“Screening Program for Efficient Clinical Trial Access”) (EORTC-1404) |
| since 2007 | Member of the SPECTA steering committee (since 7/2014) |
| since 2007 | Member of the Quality Assurance Committee (since 1/2016) |
| since 2007 | Board Member of the EORTC-Genito Urinary Cancer Group (since 2/2016) |
| since 2007 | Member of the “International Renal Cell Carcinoma-Venous Thrombus Consortium” (IRCC-VTC) |
| since 2007 | Identification and functional characterization of serum circulating microRNAs for prostate cancer risk assessment (DKFZ Hei-delberg, Working Group Clinical Genome Research, Prof. Sültmann). |
| since 2007 | Development of new prognostic biomarkers in prostate cancer, Laboratory of Biosignaling & Therapeutics, Department of Cellular and Molecular Medicine, KU Leuven, Belgium (Prof. Bollen) |
| since 2007 | Molecular Characterization of Tumor Suppressor and Oncomicro-RNAs in vitro and in vivo (Molecular Urooncology University of Würzburg, Dr. Kneitz; Urooncological Research Laboratory University of Bern, Mrs. Dr. M. Kruithof-de Julio, Dr. M. Cecchini) |
| since 2007 | ICo-founder and Steering Committee Member of the “European Clinical and Translational High Risk Prostate Cancer Research Group” |
| since 2007 | Operative treatment of the high-risk prostate cancer |
| since 2007 | Identification and molecular characterization of lethal prostate cancer |
| since 2007 | Biomarker identification and validation |